Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer

Autor: Zsolt Lengyel, Katalin Borbély, Zsuzsanna Németh, Erika Hitre, Wouter Wijker
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Oncology
Male
Cancer Research
medicine.medical_specialty
Colorectal cancer
medicine.medical_treatment
First line
030218 nuclear medicine & medical imaging
Pathology and Forensic Medicine
Targeted therapy
Metastasis
03 medical and health sciences
0302 clinical medicine
Fluorodeoxyglucose F18
Internal medicine
Positron Emission Tomography Computed Tomography
Antineoplastic Combined Chemotherapy Protocols
medicine
Overall survival
Biomarkers
Tumor
Humans
Progression-free survival
Aged
Chemotherapy
business.industry
Metastatic colorectal cancer
Liver Neoplasms
Response
General Medicine
Middle Aged
medicine.disease
Prognosis
Predictive value
FDG-PET/CT
Standardized added metabolic activity
Survival Rate
030220 oncology & carcinogenesis
Interim
Disease Progression
Progression free survival
Original Article
Female
Radiopharmaceuticals
business
Colorectal Neoplasms
Glycolysis
Follow-Up Studies
Zdroj: Pathology Oncology Research
ISSN: 1532-2807
1219-4956
Popis: We tested the prognostic relevance of metabolic parameters and their relative changes in patients with metastatic colorectal cancer (mCRC) treated with monoclonal antibody and chemotherapy. SUVmax (standardized uptake volume), SAM (standardized added metabolic activity) and TLG (total lesion glycolysis) are assessed with 18F-fluorodeoxyglucosepositron emission tomography and computed tomography (FDG-PET/CT) to evaluate total metabolic activity of malignant processes. Our purpose was to investigate the change of glucose metabolism in relation to PFS (progression free survival) and OS (overall survival). Fifty-three patients with mCRC with at least one measurable liver metastasis were included in this prospective, multi-center, early exploratory study. All patients were treated with first-line chemotherapy and targeted therapy. Metabolic parameters, like SUVmax, SAM, normalized SAM (NSAM) and TLG were assessed by FDG-PET/CT, carried out at baseline (scan-1) and after two therapeutic cycle (scan-2). Our results suggested neither SUVmax nor TLG have such prognostic value as NSAM in liver metastases of colorectal cancer. The parameters after the two cycles of chemotherapy proved to be better predictors of the clinical outcome. NSAM after two cycles of treatment has a statistically significant predictive value on OS, while SAM was predictive to the PFS. The follow up normalized SAM after 2 cycles of first line oncotherapy was demonstrated to be useful as prognostic biomarkers for OS in metastatic colorectal cancer. We should introduce this measurement in metastatic colorectal cancer if there is at least one metastasis in the liver. Electronic supplementary material The online version of this article (10.1007/s12253-020-00865-5) contains supplementary material, which is available to authorized users.
Databáze: OpenAIRE
Externí odkaz: